NCT04777175 2024-09-19
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Recruiting
Clinical Trials
8 trialsNCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT00310128 2016-02-03
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Phase 2 Withdrawn
NCT00024115 2015-04-28
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT00052403 2014-01-16
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00324831 2013-12-18
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 3 Suspended
NCT00002482 2013-11-06
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00265928 2008-01-28
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated